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Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent significant morbidity and mortality. The
mainstay of therapy has been vitamin-K antagonist therapy bridged with parenteral anticoagulants.The recent approval of new oral
anticoagulants (NOACs: apixaban, dabigatran, and rivaroxaban) has generated significant interest in their role in managing venous
thromboembolism, especially pulmonary embolism due to their improved pharmacokinetic and pharmacodynamic profiles,
predictable anticoagulant response, and lack of required efficacy monitoring.This paper addresses the available literature, on-going
clinical trials, highlights critical points, and discusses potential advantages and disadvantages of the new oral anticoagulants in
patients with pulmonary embolism.
1. Introduction
Pulmonary embolism (PE) is a common, potentially fatal
disease with an annual incidence of approximately 70 cases
per 100 000 people [1, 2]. Patients generally require hospital-
ization and recurrence is common [3]. In addition to signifi-
cant morbidity andmortality, treatment costs associated with
thrombosis and the arising postthrombotic syndromes are
staggering, with costs exceeding 500 million dollars annually
in the United States [1, 4, 5].
Themainstay of treatment for the past fifty years has been
warfarin therapy, overlapped with a parenteral anticoagulant
until the vitamin K antagonist (VKA) is fully therapeutic [2,
5].While highly effective at reducingmorbidity andmortality
associated with PE, VKA therapy poses challenges, including
variability in drug response, patient compliance, and drug-
drug, drug-disease, and drug-diet interactions [6–9]. Great
interest has been generated regarding the recently marketed
new oral anticoagulants (NOACs) and their potential role as
alternative anticoagulant therapies.
2. Risk Assessment in Pulmonary Embolism
Pulmonary embolism is a serious and potentially fatal com-
plication of a venous thrombotic event (VTE). Despite clin-
ical trials yielding similar estimates for safety and efficacy
in overall treatment when comparing deep vein thrombosis
(DVT) and PE, patients with PE incur additional risks not
seen in patients with DVT alone. The impact of PE on mor-
tality is striking, with significant increases in the risk of
death at both 30 and 90 days after event [10]. In addition to
increasing mortality, PE also has significant impact on mor-
bidity. Cardiorespiratory impairment, including pulmonary
hypertension, can result in chronic and irreversible health
concerns. Additionally, recurrent episodes of either VTE or
PE are approximately 40% higher in patients with history
of a PE, propagating the dangers of VTE and PE into the
future [5, 10]. These factors culminate in an essential need
for safe and effective anticoagulant treatments for pulmonary
embolism.
Three new oral anticoagulants (apixaban, dabigatran,
and rivaroxaban) are the newest to enter the anticoagulant
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armamentarium. The available data on each agent in the
treatment of PE, their respective mechanisms of action,
pharmacokinetic profiles, and potential places in therapy are
discussed.
3. Relevant Pharmacokinetic and
Pharmacodynamic Clinical Pearls
Each of the NOACs has unique pharmacokinetic and phar-
macodynamic properties that clinicians must consider when
selecting oral anticoagulant therapy. The comparative phar-
macokinetic profiles for the NOACs in respect to warfarin
are provided in Table 1. The newer agents have a more rapid
onset and shorter duration of activity than warfarin. This
suggests that standard management of starting a parenteral
anticoagulant simultaneous to an oral VKA (bridging) ther-
apy upon initiation or interruption of therapy may become
unnecessary in some patients. An important caveat to this
change is that some Phase II and III data indicate a potential
need for higher doses for some of the NOACs during the first
few weeks of treating an acute thrombotic event, requiring
close attention to dosing recommendations and adjustments
[11, 12]. Clinical trials with dabigatran, however, have utilized
a study design requiring a lead-in treatment period with
a parenteral anticoagulant prior to the initiation of study
medication thereby making a decision about the utility of
dabigatran as primary treatment for VTE an unanswered
clinical question [13, 14]. The reader is directed to Section 4
of this paper for more details on available clinical trials.
An equally important point is the dosing schedules of
the NOACs range from once to twice daily, despite relatively
short half-lives. This makes compliance, appropriate coun-
seling and monitoring imperative components to successful
therapy. Although theNOACs do not have the dietary restric-
tions of warfarin, an important caveat for rivaroxaban is that
higher doses (i.e., >10mg/day) need to be given with food to
enhance bioavailability. Additionally, the rivaroxaban pack-
age insert recommends avoiding administration via feeding
tube due to concerns of decreased bioavailability.While there
are no dietary restrictions with dabigatran, the dosage form
cannot be crushed or chewed as bioavailability increases
well above therapeutic levels. Dabigatran must also be stored
in the original container to prevent capsule degradation,
with the medication expiring 4 months after opening of the
original container. Dabigatran therefore cannot be placed in
a pill box or organizer because of its hygroscopic tendencies.
The NOACs have fewer drug interactions than warfarin;
however vigilance with patient’s medication profiles and
concomitant medications is necessary as the NOACs are
subject to drug-drug interactions via the cytochrome p450
and p-glycoprotein systems (Table 2). Note that the suggested
dosing alterations provided in Table 2 for dabigatran and
apixaban are those noted in the package inserts currently
approved under the indications of nonvalvular atrial fibrilla-
tion (AF). In many cases, the treatment doses utilized for PE
are higher than those approved for other indications, making
caution necessary when applying available dose adjustment
recommendations to patients with VTE. If these agents
receive FDA approval for the treatment of PE, updates to the
package inserts to address drug interactions and recommen-
dations for adjustment to the newly approved doses will be
imperative. As rivaroxaban is now approved for the treatment
of PE as well as nonvalvular AFIB and DVT prevention, the
table highlights the interactions consistent with these dosing
schedules.
Lastly, the varying degree of renal elimination and altered
response in patients with evidence of renal dysfunction
adds to the clinical complexity for the appropriate patient
selection. Dabigatran, rivaroxaban, and apixaban have FDA
approved dosing adjustments for patients with nonvalvular
AF and who have compromised renal function. For dabi-
gatran and rivaroxaban, these renal dosing recommenda-
tions, while FDA-approved, are based upon pharmacokinetic
studies and have not been studied clinically. When apixaban
was studied, the clinical trials took into account the patients
level of renal function and so the dose adjustment in the
package insert is based on validated data from the clinical
trial. Therefore, the FDA approved dose for apixiban is
to reduce the dose in patients with two of the following
characteristics: age ≥80 years, body weight <60 kg or serum
creatinine ≥1.5mg/dL (Table 2). Additional considerations
are necessary in patients with both renal dysfunction and
concurrent drug-drug interactions, as the pharmacokinetics
become even more uncertain. Consideration for continued
use and referral to a specialized anticoagulation clinic or
service offers the prescriber with a comprehensive assessment
of the appropriateness of patient selection for the NOACs.
The predictable pharmacokinetic profile of the newer
NOACs results in less variability in drug response thereby
negating the need for individualized therapeutic monitoring
as required with VKA. Although the newer agents can alter
coagulation assays (Table 1), there is an inconsistent relation-
ship between drug effect and assay response to allow clinical
utility of laboratorymonitoring. Although there is a clinically
appealing feature of these new agents, this poses a therapeutic
challengewhen bleeding occurs or urgent reversal is required,
as traditional coagulation assays do not provide quantitative
evidence for the intensity of anticoagulant effect. However,
these assays can be used to qualitatively assess the presence
of drug and thereby guide course of action in the event
of emergency. Conversely, given the relative insensitivity of
traditional assays (such as the INR and aPTT) to the NOACs,
normalization of the assay may not always indicate lack of
drug or complete reversal of the pharmacologic effect [15, 16].
The lack of a reversal agent for the NOACs remains one of
the most important clinical concerns with these new agents.
As the NOACs pharmacologically do not induce clotting
factor deficiencies as a mechanism of action, the utility of re-
placement products such as fresh frozen plasma (FFP) is lim-
ited. Since the NOACs represent inhibitors of the coagulation
cascade, reversal will remain a challenge until an antidote is
developed and tested clinically.
Currently, only summary recommendations regarding
the management of bleeding or “reversal” of the NOACs can
be made. Although there are published studies, many are ex
vivo or animal studies that cannot reliably predict an in-vivo
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Table 1: Comparison of the pharmacokinetic and pharmacodynamic features of oral anticoagulant therapies [15, 18, 21, 23–31].
Characteristic Warfarin Apixaban Dabigatran Rivaroxaban
Mechanism of action VKORC1 enzyme inhibitor Direct
∧ Factor Xa inhibitor Direct∧ Factor IIa
(Thrombin) inhibitor
Direct∧ Factor Xa
inhibitor
Prodrug No No Yes No
Approved indications
VTE prevention
VTE treatment
Atrial fibrillation
Valvular heart disease
(all approved in EMA, HC,
FDA)
VTE prevention
(EMA, HC)
Nonvalvular AF
(EMA, HC, FDA)
VTE prevention
(EMA, HC)
Nonvalvular AF
(EMA, HC, FDA)
VTE prevention
(EMA, HC, FDA)
Nonvalvular AF
(EMA, HC, FDA)
VTE treatment
(EMA, HC, FDA)
FDA black box warnings
Agent can cause major or
fatal bleeding; Regular INR
monitoring is necessary;
drugs, dietary changes, and
other factors affect INR
levels (FDA)
Discontinuation in patients
without adequate
continuous anticoagulation
increases the risk of stroke
(FDA)
None to date
Discontinuing places
patients at an
increased risk of
thrombotic events;
Risk of
spinal/epidural
hematoma during
neuraxial
anesthesia/spinal
puncture (FDA)
Dosing Variable, patient specific
Fixed, twice daily
With dose reduction in two
of the following patients:
(per FDA)
(1) Age ≥ 80 years
(2) Weight ≤ 60 kg
(3) Serum creatinine
≥1.5mg/dL
Fixed, twice daily
With dose reduction in
patients with renal
dysfunction (per FDA)
VTE prevention and
nonvalvular AF:
Fixed, once daily
With dose reduction
in patients with renal
dysfunction (per
FDA)
VTE treatment:
Fixed, twice daily ×
3weeks then fixed,
once daily
Not to be used if ClCr
<30mL/min
𝑇max (h) 4 1–3 1–3 2–4
Half-life (h) 20–60 12 12–17 5–9
Bioavailability (F) 100% 50% 6%(∼75% if capsule opened)
10mg: 80–100%
(regardless of food)
20mg: 66% (without
food).
Food increases
absorption#
Renal Clearance >90% as inactivemetabolites 25% 80%
∗
36% unchanged
drug∗
33% as inactive
metabolites
Mostly via secretion
not glomerular
filtration
CYP metabolism+
>90%
(S-enantiomer is a substrate
for 2C9 and 2C19 while
R-enantiomer is a substrate
for 1A1, 1A2, and 3A4 )
15%
(primary substrate for
CYP3A4; minor
contributions by others,
without active metabolites)
No
30%
(substrate for
CYP3A4, CYP2J2)
P-glycoprotein (P-gp)+ No Yes Yes Yes
Dietary considerations Dietary vitamin K None None
VTE prevention dose:
does not specify
AFIB: Take with
evening meal
VTE treatment: Take
with food
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Table 1: Continued.
Characteristic Warfarin Apixaban Dabigatran Rivaroxaban
Influence on routine
coagulation assay
Protime (PT) ↑ ↑ ↑ ↑
aPTT No/↑ ↑ ↑ ↑
Thrombin time (TT) No No ↑↑ No
Coagulation assay
used to monitor efficacy INR (Protime) None None None
Clinically validated
Reversal agent
Vitamin K, FFP, PCC,
Factor VIIa, aPCC None None None
EMA: European Medicines Agency; HC: Health Canada; FDA: U.S. Food and Drug Administration
AF: Atrial Fibrillation; CYP: cytochrome P450; VKORC1: C1 subunit of the vitaminK epoxide reductase enzyme; FFP: Fresh Frozen Plasma; PCC: Prothrombin
Complex Concentrate.
∧Does not bind to antithrombin.
#Rivaroxaban 15mg tablet, if available, should be taken with food.
∗Dose adjustment for level of renal dysfunction required.
+Potential source for drug-drug interactions—review full package insert for details.
response and therefore recommendations remain inconclu-
sive. In vitro publications in humans are sparse and primarily
limited to case reports [17]. For reversal of dabigatran, the use
of activated charcoal and dialysis in cases of life threatening
bleeding or overdose can be considered [18]. Activated Factor
VIIa (Novoseven) is a seemingly attractive option though it
has not been studied in humans. In animal models, bleeding
complications were not reliably and consistently reversed
[19], and use in the nonhemophiliac population has been
associated with an increased risk of thrombosis [20].
A nonactivated 4-factor PCC product (Cofact) failed to
show reversal in coagulation parameters induced by dabigat-
ran in a randomized, placebo-controlled, crossover study in
healthy subjects. In this study, bleeding was not an accessible
outcome [15]. van Ryn and colleagues performed an in vitro
study using nonactivated 4-factor PCCs (Beriplex and Octa-
plex), an activated PCC product (FEIBA), and an activated
Factor VII (Novoseven) and found a reduced bleeding time
after administration, despite failure to reverse coagulation
parameters such as aPTT and thrombin time [16]. These
animal model studies suggest a potential lack of correlation
between changes in coagulation parameters and bleeding
for dabigatran, and further study is needed to confirm this
hypothesis [15].
In regard to rivaroxaban, dialysis is not a viable option due
to high protein binding (92–95%) [21], and no data on acti-
vated charcoal could be found.Animal studies using activated
Factor VII (Novoseven) show only modest effect on reducing
bleeding, and there are no human clinical data to support
routine use [22]. Additionally, the concern of increased risk
of thrombosis remains with activated Factor VII use [19]. A
randomized, placebo-controlled, crossover study in healthy
subjects suggested that a nonactivated 4-factor PCC product
(Cofact) used in healthy adults could reverse rivaroxaban
effect on the PT; however it is unknown whether this trans-
lates into decreasing bleeding [15].
No data or recommendations currently exist for reversal
of apixaban therapy. To complicate translation of this research
into clinical practice, nonactivated 4-factor PCCs are unavail-
able in the United States, and the only 4-factor PCC available
is the activated FEIBA product. Institutions are therefore
left with the development of institution-specific policies for
reversal based upon the foundation of supportive care and
local measures to stop bleeding, the availability of the local
medical expertise, an understanding of available literature
and reversal agents, and cost.
4. Anticoagulant Therapy for Treatment of
Pulmonary Embolism
4.1. Apixaban. Limited data exist to determine the safety and
efficacy of apixaban for the treatment of PE. The AMPLIFY
(NCT00643201) trial is a Phase III, randomized, double-
blind, double-dummy, noninferiority trial ongoing to assess
apixaban in the initial treatment of VTE [33]. AMPLIFY is
currently enrolling patients in a 6-month study, comparing
dose-adjusted warfarin (INR goal 2.0–3.0) with parenteral
anticoagulant bridge to apixaban 10mg twice daily for 7 days
followed by apixaban 5mg tablets twice daily. The study is
expected to enroll 4816 in 471 study locations and is expected
to close inMarch 2013with a primary outcome of a composite
time to recurrent VTE or death [33]. No safety or efficacy data
are presently available from the AMPLIFY trial.
AMPLIFY-EXT is a randomized, double-blind study
evaluating the safety and efficacy of apixaban for the extended
treatment of DVT and PE over a 12-month period following
the initial 6–12 months of anticoagulation therapy [34]. Sub-
jects were randomized to apixaban 2.5mg or 5mg twice
daily or placebo and were eligible if they were 18 years of
age or older, had objective confirmed proximal DVT of the
leg(s) or PE, had finished 6–12 months of standard antico-
agulant therapy, or had completed treatment with apixaban
or enoxaparin and warfarin as part of the AMPLIFY trial,
had no symptomatic recurrent of VTE during prior antico-
agulant therapy, and had clinical equipoise to continue or
cease anticoagulation therapy. Patients were excluded if they
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Table 2: Selected P-glycoprotein and Cytochrome P450 3A4 drug interactions with NOAC based on current FDA-approved indications
[18, 21, 31, 32].
Medications+ Mechanism of Interaction Dabigatran
#
(Pradaxa)
Rivaroxaban∧
(Xarelto)
Apixaban
(Eliquis)
Rifampin P-glycoprotein inducer Avoid combination Avoid Avoid
Carbamazepine, phenytoin,
St. John’s wort
P-glycoprotein inducers
and
Strong 3A4 inducers
Avoid Avoid Avoid
Dronedarone P-glycoprotein inhibitors
For CrCl 30–50mL/min:
Dose reduction suggested
in dosing for Atrial
Fibrillation
For CrCl < 30mL/min:
Aviod
Not addressed in
Package Insert Not addressed
Systemic ketoconazole
Itraconazole
P-glycoprotein inhibitors
and
Strong 3A4 inhibitors
For CrCl 30–50mL/min:
Dose reduction suggested
in dosing for Atrial
Fibrillation
Avoid
Reduce dose in 1/2 for
those starting on the full
dose of 5mg BID%
lopinavir/ritonavir,
ritonavir,
indinavir/ritonavir,
conivaptan
P-glycoprotein inhibitors
and
Strong 3A4 inhibitor
Not addressed in Package
Insert Avoid
Reduce dose in 1/2 for
those starting on the full
dose of 5mg BID%
Verapamil, amiodarone,
quinidine, P-glycoprotein inhibitors
For CrCl 30–50mL/min:
No dose adjustment
needed, monitor clinical
course
For CrCl < 30mL/min:
Aviod
Not addressed in
Package Insert
Reduce dose in 1/2 for
those starting on the full
dose of 5mg BID%
Clarithromycin P-glycoprotein inducersand strong 3A4 inducers
For CrCl < 30mL/min
Avoid
For CrCl 30–50mL/min:
No dose adjustment
needed, monitor clinical
course
Unclear: refer to
package insert.
Reduce dose in 1/2 for
those starting on the full
dose of 5mg BID%
CrCl: creatinine clearance as determined by Crockcoft-Gault equation.
#Dabigatran etexilate (prodrug) uses the p-glycoprotein transport system. It is not a substrate, inducer, or inhibitor of the cytochrome p450 system.
∧Rivaroxaban is a substrate for cytochrome p450 as well as p-glycoprotein.
+Listed medications are representatives of potent 3A4 inhibitors and may not be comprehensive.
%Those patients who need to start at 2.5mg BID should avoid this combination.
had contraindication to continued anticoagulant therapy,
had dual antiplatelet therapy, were on aspirin doses greater
than 165mg daily, had elevated liver function tests, or has
depressed hematologic markers.
The majority of patients on apixaban in AMPLIFY-EXT
weighed greater than 60 kg (92.6%). Serum creatinines (for
dose adjustment, per the package insert) were not provided;
though the majority of patients on apixaban (99.8%) had
a calculated creatinine clearance greater than 30mL/min,
91.8% had a calculated creatinine clearance greater than
50mL/min. Of the subjects on apixaban, 98.3% completed 6–
12months of prior anticoagulation therapy, as opposed to less
than 6 months and more than 12 months, though no further
informationwas provided as to the exact discontinuation date
of the initial anticoagulant therapy. Patients lost to follow
were classified as having the primary outcome event and
negative for reaching the primary safety endpoint. Study end-
points are presented in Table 3.
Based upon information provided by the authors of the
source article, apixaban 5mg twice daily lowered the rate of
recurrent, nonfatal pulmonary embolism [23], when therapy
was extended one year beyond the initial anticoagulation
period when compared to placebo. Until the results from
AMPLIFY are available, it remains unknown if apixaban is
safe and effective in the primary treatment of VTE with
pulmonary embolism [33].
4.2. Dabigatran EtexilateMesylate. Dabigatran, an oral direct
thrombin inhibitor, has been FDA approved for nonvalvular
atrial fibrillation and is also approved in Europe and Canada
forVTE prevention. Currently, dabigatran is not approved for
the treatment of VTE in Canada, Europe, or the United States
ofAmerica, and applications to the respective regulatory bod-
ies (EMA, HC, and FDA) have not been submitted. Presently
four Phase III clinical trials, RE-COVER, RE-COVER-II, RE-
MEDY (NCT00329238), and RE-SONATE (NCT00558259),
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Table 3: Outcomes of apixaban in AMPLIFY-EXT [34].
Outcome Apixaban 2.5mg(𝑛 = 840; 13 LTF)
Apixaban 5mg
(𝑛 = 813; 20 LTF)
Placebo
(𝑛 = 829; 19 LTF)
Primary efficacy endpoint: composite of symptomatic recurrent vte or
death from any cause
32 (3.8%) 34 (4.2%)
96 (11.6%)RR versus placebo RR versus placebo
0.33 (0.22–0.48) 0.36 (0.25–0.53)
Secondary efficacy endpoint: symptomatic recurrent VTE or death
related to VTE
14 (1.7%) 14 (1.7%)
73 (8.8%)RR versus placebo RR versus placebo
0.19 (0.11–0.33) 0.20 (0.11–0.34)
Additional endpoint added after trial initiation: composite of
symptomatic recurrent VTE, death related to VTE, myocardial
infarction, stroke, or death related to cardiovascular cause
18 (2.1%) 19 (2.3%)
83 (10%)RR versus placebo RR versus placebo
0.21 (0.13–0.35) 0.23 (0.14–0.38)
Primary safety endpoint: major bleeding∧
2 (0.2%) 1 (0.1%)
4 (0.5%)
RR versus placebo RR versus placebo
0.49 (0.09–2.64) 0.25 (0.03–2.24)
Secondary safety endpoint: major or clinically relevant nonmajor
bleeding∧∧
27 (3.2%) 35 (4.3%)
22 (2.7%)RR versus placebo RR versus placebo
1.2 (0.69–2.10) 1.62 (0.96–2.73)
Recurrent fatal PE or death where PE could not be excluded
2 (0.2%) 3 (0.4%)
7 (0.8%)RR versus placebo RR versus placebo
0.28 (0.06–1.35) 0.43 (0.11–1.68)
Recurrent nonFatal PE
8 (1%) 4 (0.5%)
15 (1.8%)RR versus placebo RR versus placebo
0.53 (0.22–1.23) 0.27 (0.09–0.82)
Study conclusion
Extension with 12months of apixaban 2.5mg or 5mg twice daily
therapy reduced the risk of recurrent VTE and recurrent nonfatal
PE, without increasing the risk of major bleeding.
NR: not reported, LTF: lost to follow (classified as having the primary efficacy endpoint).
∧Major bleeding as defined in AMPLIFY-EXT: clinical overt bleeding, with associated fall in hemoglobin of at least 2 g per deciliter, the need for transfusion
of 2 or more units of red blood cells, involving a critical site or was fatal.
∧∧Nonmajor bleeding as defined in AMPLIFY-EXT: bleeding that did not meet criteria for major bleeding but AHT was associated with the need for medical
intervention, unscheduled contact with a physician, interruption or discontinuation of the study drug, or discomfort or impairment of activities of daily living.
In addition, any bleeding compromising hemodynamics, leading to hospitalization, development of subcutaneous hematoma larger than 25 cm2 or 100 cm2 if
traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis of more than 5minutes duration, or was repetitive, spontaneous gingival
bleeding, spontaneous macroscopic hematuria lasting great than 24 hours, macroscopic gastrointestinal hemorrhage, and hemoptysis not occurring with PE.
have been completed to assess the efficacy of dabigatran in
the treatment of VTE, with or without PE, though only RE-
COVER has published full results [13, 14, 35, 36].
RE-COVER is a randomized, double-blind, double-dum-
my, noninferiority trial conducted in 228 centers world-wide,
enrolling 2564 patients [14]. Patients were eligible if they
were 18 years of age or older and had objective confirmed
proximal DVT of the leg(s) or PE. Patients were excluded if
they had VTE symptoms for more than 14 days, experiencing
hemodynamic instability requiring thrombolytic therapy,
had recent cardiovascular event, or were at high risk for
bleeding.
The design of RECOVER was unique in that all patients
received a parenteral anticoagulant (intravenous unfraction-
ated heparin or subcutaneous lowmolecular weight heparin)
for the first 6 days, while warfarin dosing was being adjusted
to achieve a target INR of 2-3 by sham INR. After that time,
patients continued their blinded randomized assignment of
either Dabigatran (150mg twice daily) or warfarin (dose-
adjusted to a target INR of 2.0–3.0). Because parenteral
anticoagulation was used during the first week, larger initial
dabigatran doses, as seen in other NOACs studies, were not
utilized as part of this protocol.
RE-COVER II was of similar design, enrolling 2568 pa-
tients and was conducted to confirm the previous results and
gather data sufficient for subgroup analyses [35]. Study end-
points are presented in Table 4.
All RE-COVER study patients on dabigatran had a crea-
tinine clearance above 50mL/min (mean 105.8 ± 40.7) with
a median weight of 84 kg (range: 38–175). The proportion of
cancer patients, those with the highest risk of development
and morbidity associated with PE, were small in the dabiga-
tran and warfarin groups, 5.0% and 4.5%, respectively [14].
Subgroup analysis did not indicate differences in the
primary endpoint in relation to gender, age, or race or those
presenting with initial symptomatic PE or active cancer at
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Table 4: Outcomes of dabigatran in VTE studies [14, 35].
Outcome RE-COVER(dabigatran versus warfarin)
RE-COVER II
(dabigatran versus warfarin)
Primary efficacy endpoint:
recurrent symptomatic VTE or
VTE-Related Death
2.4% versus 2.1%, HR 1.10 (95% CI 0.65–1.84) 2.4% versus 2.2%, HR 1.08 (95% CI 0.64–1.8 )
Secondary efficacy endpoint:
recurrent, nonfatal PE 1.0% versus 0.6%, HR 1.85 (07.4–4.64) NR
Total days overlap between
warfarin/dabigatran and parenteral
anticoagulant
5–10 days (mean = 10 days) 5–11 days (mean NR)
Major Bleeding∧ 1.6% versus 1.9%, HR 0.82 (95% CI 0.45–1.48) 1.1% versus 1.7%, HR 0.69 (95% CI 0.36–1.32)
Major or clinically relevant
non-major bleeding∧∧ 5.6% versus 8.8%, HR 0.63 (95% CI 0.47–0.84) NR
Any bleeding 16.1% versus 21.9%, HR 0.71 (95% CI 0.59–0.85) 15.6% versus 22.1%, HR 0.67 (95% CI 0.56–0.81)
Death 1.6% versus 1.7%, HR 0.95 (0.53–1.79) 1.9% in both groups
Warfarin TTR 60% NR
Study conclusion Dabigatran is noninferior to warfarinDabigatran is not superior to warfarin
Dabigatran is noninferior to warfarin
Dabigatran is not superior to warfarin
NR: not reported, TTR: time in therapeutic range.
∧Major bleeding as defined in RE-COVER: Clinical overt bleeding, with associated fall in hemoglobin of at least 20 g per liter, the need for transfusion of 2 or
more units of red blood cells, involving a critical site or was fatal.
∧∧Minor bleeding as defined in RE-COVER: spontaneous skin hematoma of at least 25 cm2, spontaneous nose bleed of more than 5 minutes in duration,
macroscopic hematuria lastingmore than 24 hours, spontaneous rectal bleeding, gingival bleeding of greater than 5minutes, bleeding leading to hospitalization
and/or requiring surgical treatment, bleeding leading to transfusion of less than 2 units of red blood cells, or any other clinically relevant bleeding per the
investigator.
baseline. Likewise, the rate of recurrent VTE in patients with
previous VTE was not statistically different in the two treat-
ment groups (𝑃 = 0.09), though trended to favor warfarin
therapy [14].
Comparison data were not available in RE-COVER II as
this was presented in abstract form only. Study authors note
that a full publication is pending.
In RE-COVER, dabigatran 150mg twice daily was nonin-
ferior, but not superior to dose-adjusted warfarinmanaged to
a time in therapeutic range (TTR) of 60 percent. The rate of
recurrent PE was higher in the dabigatran group (1% versus
0.6%, HR 1.85, 95% CI 0.74–4.64), though not statistically
different. The dabigatran 150mg twice daily dose was also
utilized in the RE-LY atrial fibrillation study. Noting that the
18 113 patients were not randomized to correct for VTE risk
factors, nor were they reported, the rates of PE development
in the dabigatran and warfarin groups were 0.15% per year
and 0.09% per year respectively (Relative Risk 1.61, 95% CI
0.76–3.42, 𝑃 = 0.21, warfarin mean TTR 64%) [14].
The RE-MEDY (NCT00329238) and RE-SONATE
(NCT00558259) trials have both been completed, with data
collection terminating in October 2010 and February 2011,
respectively. RE-MEDY is a randomized, double-blind, mul-
ticenter, parallel-group, active controlled study to compare
the efficacy and safety of dabigatran 150mg twice daily to
dose-adjustedwarfarin (INR target 2.0–3.0) for the secondary
prevention of VTE. A total of 2867 patients in 275 study
locations were followed for a total of 36 months to the pri-
mary outcome of composite recurrent VTE or VTE death at
18 and 36 months [13].
RE-SONATE is a randomized, double-blind, multicen-
ter, parallel-group, prevention study to compare dabigatran
150mg twice daily versus matching placebo in the long-
term prevention of recurrent, symptomatic VTE in patients
with history of DVT or PE who completed 6–18 months of
treatment with VKA therapy. Total study enrollment is 1353
patients in 147 study locations. The primary study endpoint
is time to centrally confirmed VTE over the 6-month study
period [36].
Bleeding remains a main safety concern with dabigatran
and the NOACs. In the setting of acute VTE, warfarin
showed slightly higher rates of nonmajor bleeding, though
no difference in major bleeding outcomes was found [14].
Despite the lack of difference in clinical trials, Phase IV data
with the dabigitran 150mg twice daily utilized for stroke
prevention in AF still raise bleeding as a significant concern.
On December 7, 2011, the FDA initiated an investigation
into serious bleeding events associated with dabigatran [37].
Likewise, the Institute for Safe Medication Practices reported
that the FDA received nearly three times as many serious
and fatal side effects in 2011 with dabigatran as compared to
warfarin (3781 versus 1106.) This report also concluded that
dabigatran surpassed all other regularly monitored drugs in
categories such as deaths (542), hemorrhage (2,367), acute
renal failure (291), and stroke (64) and was suspected in 15
cases of liver failure [38].
4.3. Rivaroxaban. Rivaroxaban, an oral direct Factor Xa
inhibitor, has been FDA approved for both nonvalvular atrial
fibrillation and VTE prevention and in Canada, Europe,
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and the United States for VTE treatment. Presently, three
Phase III clinical trials, EINSTEIN-DVT, EINSTEIN-PE, and
EINSTEIN-Extension, have been completed to assess the
efficacy of rivaroxaban treatment in VTE [11, 39, 40].
EINSTEIN-DVT was an open label, randomized, mul-
ticenter, noninferiority trial enrolling 3449 patients with
symptomatic DVT without PE [11]. Patients were eligible if
they were 18 years of age or older, had objectively confirmed
proximal deep vein thrombosis (DVT), and were without
symptomatic pulmonary embolism. Patients were excluded if
they received therapeutic doses of low-molecular weight hep-
arin, fondaparinux, or unfractionated-heparin for more than
48 hours or if they had received more than a single dose of a
vitamin K antagonist before randomization, if they had been
treated with thrombectomy, a vena cava filter, or a fibrinolytic
agents for the current episode of thrombosis, or if they had
a contraindications listed in the labeling of the medications
used, another indication for warfarin, creatinine clearance
<30mL/min; clinically significant liver disease or an ala-
nine aminotransferase level that was three times the upper
limit of normal, active, or high risk for bleeding, bacterial
endocarditis, systolic blood pressure greater than 180mmHg,
or diastolic blood pressure greater than 110mmHg; child
bearing potential without proper contraception, pregnancy,
or breast-feeding; concomitant use of strong cytochrome
P450 3A4 inhibitors; participation in another study within
3 days before screening; and life expectancy of less than 3
months.
In EINSTEIN-DVT, patients were either randomized to
either rivaroxaban (15mg orally twice daily for 3 weeks,
followed by 20mg daily for 3 to 12 months) or a parenteral
anticoagulant (enoxaparin 1mg/kg of body weight subcuta-
neously twice daily) overlapping with a vitamin K antagonist
such as warfarin or acenocoumarol (dose-adjusted to a target
INR of 2.0–3.0) [11]. Parenteral anticoagulation was contin-
ued for at least five days until an INR above 2.0 was achieved
for two consecutive days. Study endpoints are presented in
Table 4. In EINSTEIN DVT, rivaroxaban was noninferior
(𝑃 < 0.001) but not superior (𝑃 = 0.08) to dose-adjusted
warfarin/acenocoumarol managed to a time in TTR of 57.7%
for the primary endpoint of symptomatic recurrent VTE,
defined as the composite of DVT or nonfatal or fatal PE.
Efficacy was maintained throughout the study, even during
the time of transition from twice daily dosing to once daily
dosing for rivaroxaban and across all prespecified subgroups.
Additionally, the net clinical benefit, taking into account the
primary efficacy and safety outcomes, statistically favored
rivaroxaban over parenteral anticoagulants plus VKA (2.9%
versus 4.2%, resp.; 𝑃 = 0.03). These endpoints were achieved
with no additional risk of major bleeding or the primary
composite safety endpoint of major bleeding or clinically
relevant nonmajor bleeding (Table 5).
EINSTEIN-PE was an open label, single-blinded (out-
comes assessment only), randomized,multicenter, noninferi-
ority trial enrolling 4833 patients with symptomatic PE with
or without DVT [39]. Inclusion and exclusion criteria were
similar to EINSTEIN DVT as were the treatment regimens.
The intended duration of treatment was determined by the
treating physician before randomization but was either 3
months, 6 months, or 12 months. Study endpoints are pre-
sented in Table 4. In EINSTEIN-PE, after a mean study treat-
ment duration of approximately 7.2 months in both groups,
rivaroxaban was noninferior (𝑃 < 0.003), but not superior
(𝑃 = 0.57) to dose-adjusted warfarin/acenocoumarol man-
aged to a time in TTR of 62.7% for the primary endpoint
of symptomatic recurrent VTE, defined as the composite
of DVT or nonfatal or fatal PE. Efficacy was maintained
throughout the study, even during the time of transition from
twice daily dosing to once daily dosing for rivaroxaban and
across all prespecified subgroups such as age, sex, presence
of absence of obesity, level of renal function, or extent
of pulmonary embolism. However, unlike EINSTEIN-DVT,
there was no statistical difference in the net clinical benefit
taking into account the primary efficacy and safety outcomes
between the two groups (Table 4) [11]. These endpoints were
achieved with no statistically significant increase in the risk
of the primary safety outcome defined as the combination
of the first major or clinically relevant nonmajor bleeding
episodes but with a statistically significant decrease in the
risk of major bleeding between rivaroxaban versus parenteral
anticoagulant plus VKA (1.1% versus 2.2% HR = 0.85 (CI:
0.31–0.79); 𝑃 = 0.003).
EINSTEIN-Extension study was a placebo-controlled,
double-blinded, superiority trial designed to determine if
extended therapy would decrease the risk of recurrent VTE
in patients with confirmed DVT or PE previously treated
for 6–12 months with either VKA or rivaroxaban [40]. A
total of 1196 patients were enrolled into the trial with 34.1%
of the patients coming from the EINSTEIN DVT study
and 19.1% completing the EINSTEIN PE study while the
remaining 47.5% were referred from outside these studies.
Patients were randomized to receive either rivaroxaban 20mg
orally daily or placebo for a duration of 6–12months. Baseline
characteristics were similar between groups.Not surprisingly,
rivaroxaban was shown to be superior to placebo in the
primary outcome of the prevention of recurrent VTE with
a relative risk reduction of 82% (1.3% versus 7.1%, resp.,
HR = 0.18 (95% CI 0.09–0.39) 𝑃 < 0.001). The endpoint
was achieved without increasing the risk of the primary
safety outcome defined as major bleeding (0.7% versus 0%;
HR = not reported; 𝑃 = 0.11). However the incidence of
the composite endpoint of major bleed or clinically relevant
nonmajor bleeding occurred statistically more often in the
rivaroxaban group versus placebo (6% versus 1.2%; HR =
5.19 (95% CI 2.3–11.7); 𝑃 < 0.001). Additionally, the net
clinical benefit, taking into account the primary efficacy
and safety outcomes, statistically favored rivaroxaban over
placebo (2% versus 7.1%; HR = 0.28 (95% CI 0.15–0.53;
𝑃 < 0.001). Overall, extended therapy prevented 34 recurrent
events at the cost of 4 major bleeding events, nonfatal and an
increased risk of clinically relevant nonmajor bleeding events
compared to placebo.
The EINSTEIN studies, although large and well executed,
have the limitation of an open label design lending toward
potential bias, although the investigators have indicated that
this was unlikely to bias in favor of rivaroxaban. Additionally
the use of a placebo control for the extension trial provides
little assistance in comparing it against existing therapy,
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Table 5: Outcomes of rivaroxaban in VTE Studies [11, 40].
Outcome EINSTEIN-DVT(rivaroxaban versus VKA + parenteral )
EINSTEIN-PE
(rivaroxaban versus VKA + parenteral
agent)
Primary efficacy endpoint:
noninferiority
Recurrent symptomatic VTE
2.1% versus 3.0%, 2.1% versus 1.8%,
HR = 0.68 (95% CI 0.44–1.04) HR = 1.12 (95% CI 0.75–1.68)
𝑃 < 0.001 𝑃 = 0.003
# recurrent events that were
any type of PE 25 versus 24 32 versus 27
Secondary efficacy endpoint:
All-cause mortality
2.2% versus 2.9% 2.4% versus 2.1%
HR = 0.67 (95% CI 0.44–1.02) HR = 1.13 (95% CI 0.77–1.65)
𝑃 = 0.06 𝑃 = 0.53
Net clinical benefit
2.9% versus 4.2% 3.4% versus 4.0%
HR = 0.67 (95% CI 0.47–0.95) HR = 0.85 (95% CI 0.63–1.14)
𝑃 = 0.03 𝑃 = 0.28
Primary safety outcome:
Major bleeding or clinically relevant
nonmajor bleeding
8.1% versus 8.1% 10.3% versus 11.4%
HR = 0.97 (99% CI 0.76–1.22) HR = 0.90 (95% CI 0.76–1.07)
𝑃 = 0.77 𝑃 = 0.23
Major bleeding∧
0.8% versus 1.2% 1.1% versus 2.2%
HR = 0.65 (95% CI 0.33–1.30) HR = 0.49 (95% CI 0.31–0.79)
𝑃 = 0.21 𝑃 = 0.003
Clinically relevant nonmajor
bleeding∧∧
7.36% versus 7.0% 9.5% versus 9.8%
(statistics NR) (statistics NR)
Warfarin TTR 57.7% 62.7%
Study conclusion Rivaroxaban is noninferior to warfarin.Rivaroxaban is not superior to warfarin.
Rivaroxaban is noninferior to warfarin.
Rivaroxaban is not superior to warfarin
NR: not reported, TTR: time in therapeutic range.
∧Major bleeding as defined in EINSTEIN: Clinical overt bleeding, with associated fall in hemoglobin of at least 2.0 g per deciliter, the need for transfusion of
2 or more units of red blood cells, involving a critical site or was fatal.
∧∧Clinically relevant nonmajor bleeding as defined in EINSTEIN: overt bleeding that did not meet the criteria for major bleeding but was associated with
medical intervention, unscheduled contact with a physician, interruption or discontinuation of a study drug or discomfort, or impairment of activities of daily
life.
warfarin, and its relatively short duration of follow-up (mean
of 9 months) does not clearly address safety and efficacy for
years of chronic therapy. Although secondary analyses of the
EINSTEIN studies did not identify any signals or concern for
liver toxicity or evidence of unexpected thrombotic events,
longer duration of therapy to address a chronic lifelong
condition would have been valuable [11, 40]. The most recent
update of the ACCP Guidelines on Antithrombotic Therapy
from 2012 [2] suggests extending warfarin therapy beyond 3
months in patients with unprovoked VTE who have low-to-
moderate risk of bleeding, and if bleeding risk is high, then
therapy is limited to 3 months. Having a trial that compares
the bleeding risk of a new agent against standard VKA
therapy during extension of therapy would help refine these
recommendations even further, especially if bleeding risk is
lower with the NOACs compared to VKA. The EINSTEIN
studies included a high percentage of unprovoked events
(range between 60% and 70%) and 4–6% of patients with
active cancermaking this amoderate-to-high risk population
for recurrent events that could have effectively addressed
many of these questions. Further research is therefore rec-
ommended for the chronic use of rivaroxaban for VTE
prevention after an initial event.
5. Conclusions
Based upon the data presented, dabigatran and apixaban
cannot be recommended until further safety and efficacy
data are available. Rivaroxaban however, represents the most
promising of the NOACs for treatment of PE and is indicted
in Canada and Europe for this indication and recently
received FDA approval for this indication [21]. Although the
ACCP2012Guidelines onAntithromboticTherapy published
in February 2012 indicated warfarin as the agent with the
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most sufficient data, the results of the EINSTEIN PE were
not yet available at the time of publication [2]. With the
approval of rivaroxaban for treatment of VTE (DVT and
PE) now in the USA, Canada, and Europe, this offers yet
another treatment option. However, selection of rivaroxaban
over warfarin must take into account a full assessment of an
individual’s renal function, concomitant drug therapy, and
risk for bleeding. Although rivaroxaban was shown to be
noninferior to warfarin in both the DVT and PE studies
[11, 40], the risk of major bleeding was statistically lower only
in the PE study [40]. The issue of bleeding risk is paramount
in the decision of appropriate patient selection due to the lack
of reversal agent. Comparative efficacy is also warranted in
the setting of specialized anticoagulation clinics where the
TTR is generally above 70 percent [41–45] as the current
studies achieved only a 57–62% TTR. Lastly, long-term (>12
months) comparison data against standard warfarin therapy
are lacking, and therefore recommendations for extended
therapy beyond the acute phase of treatment cannot bemade.
Based on the strength of available evidence, warfarin
proves to be a monitorable, reversible, and effective agent
in patients across the spectrum of concurrent disease and
should remain the first-line option in conjunction with ap-
propriate parenteral anticoagulation for the treatment of pul-
monary embolism, especially in patients who require chronic
therapy or therapy beyond 3 months. However, rivaroxaban
represents a viable alternative in patients with less than
optimal INR control (TTR< 60%) or inwhomwarfarinmon-
itoring and management is not possible.
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